Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

STVN - Stevanato Group S.p.A. Latest News | Finranks

Home

/

STVN

S

Stevanato Group S.p.A. (STVN)

NYQ – Real Time Price. Currency in USD

21.36

+0.31 (1.47%)

Market open: Aug 12, 2026, 12:34 PM EDT

21.05

+0.05 (0.25%)

Previous after-hours: Aug 11, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Stevanato Group Q2 Earnings Call Highlights

Stevanato Group Q2 Earnings Call Highlights

Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.

Videos

No Data

There is no data to display

Press releases

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.